Antitumor Properties of Curcumin in Breast Cancer Based on Preclinical Studies: A Systematic Review

• Published in: Cancers 2022-04, Vol.14 (9), p.2165
• Main Authors: Barcelos, Kênia Alves, Mendonça, Carolina Rodrigues, Noll, Matias, Botelho, Ana Flávia, Francischini, Cristiane Raquel Dias, Silva, Marco Augusto Machado
• Format: Article
• Language: English
• Subjects: Animal models; Antitumor activity; Apoptosis; Bias; Breast cancer; Cancer therapies; Cell cycle; Cell division; Cell growth; Chemotherapy; Clinical trials; Curcumin; Endocrine therapy; Investigations; Laboratory animals; Nanoparticles; Neoplasia; Oral administration; Radiation therapy; Reviews; Systematic Review; Tumors; Viability
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14092165

Breast cancer is one of the most common neoplasms among women. Anticancer strategies using natural formulations and phytotherapies are promising antitumor treatment alternatives. This review assesses the antitumor effects of curcumin on breast cancer reported in preclinical in vitro and in vivo animal models. We used five databases to search for preclinical studies published up to May 2021. The assessments included the effects of curcumin on the proliferation, viability, and apoptosis of breast cancer cell lineages and on tumor volume. In total, 60 articles met the inclusion criteria. Curcumin administered at different concentrations and via different routes of administration inhibited proliferation, decreased viability, and induced apoptosis in human and animal breast cancer cells. Nanoparticle formulations of curcumin administered orally, via implant, and intraperitoneally reduced the tumor volume of human and murine mammary cells in vivo. Moreover, curcumin nanoformulations exert positive effects on tumor growth inhibition in animal models of breast cancer. Further randomized clinical trials are warranted to assess the efficacy and safety of curcumin formulations for clinical use.